Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Frew

Showing results (291-300 of 316) with videos related to

Pageof 32
Sort By:
Cancers|March 14, 2026
Pharmacologic and Oncohistone Inhibition of SETD2 Converge on Genomic InstabilityAlyssa T Paparella, Ashley G Boice, In Young Park, et al.
Cancers|April 30, 2021
Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK InhibitionAntonella Catalano, Mojca Adlesic, Thorsten Kaltenbacher, et al.
International Archives of Allergy and Immunology|January 3, 2006
Allergy practice worldwide: a report by the World Allergy Organization Specialty and Training CouncilJohn O Warner, Michael A Kaliner, Carlos D Crisci, et al.
Cancer Research Communications|January 22, 2026
Novel syngeneic cell lines for studying high-risk BRAFV600E-driven colorectal cancer in vivoJasmin Traichel, Ariane Metzger, Maria Walz, et al.
British Journal of Haematology|September 12, 2025
MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapyAndrea Kuhnl, S Bouziana, S F Barrington, et al.
The World Allergy Organization Journal|January 4, 2013
What is an Allergist?: Reconciled Document Incorporating Member Society Comments, September 3, 2007Sergio Del Giacco, Lanny J Rosenwasser, Carlos D Crisci, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 8, 2008
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonistAilsa J Frew, Ralph K Lindemann, Ben P Martin, et al.
JCI Insight|November 22, 2022
ATR represents a therapeutic vulnerability in clear cell renal cell carcinomaPhilipp Seidel, Anne Rubarth, Kyra Zodel, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 2, 2007
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphomaR K Lindemann, A Newbold, K F Whitecross, et al.
Molecular and Cellular Biology|December 3, 2003
Generation and analysis of Siah2 mutant miceIan J Frew, Vicki E Hammond, Ross A Dickins, et al.
Pageof 32

Showing results (291-300 of 316) with videos related to

Sort By:
Pageof 32
Cancers|March 14, 2026
Pharmacologic and Oncohistone Inhibition of SETD2 Converge on Genomic InstabilityAlyssa T Paparella, Ashley G Boice, In Young Park, et al.
Cancers|April 30, 2021
Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK InhibitionAntonella Catalano, Mojca Adlesic, Thorsten Kaltenbacher, et al.
International Archives of Allergy and Immunology|January 3, 2006
Allergy practice worldwide: a report by the World Allergy Organization Specialty and Training CouncilJohn O Warner, Michael A Kaliner, Carlos D Crisci, et al.
Cancer Research Communications|January 22, 2026
Novel syngeneic cell lines for studying high-risk BRAFV600E-driven colorectal cancer in vivoJasmin Traichel, Ariane Metzger, Maria Walz, et al.
British Journal of Haematology|September 12, 2025
MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapyAndrea Kuhnl, S Bouziana, S F Barrington, et al.
The World Allergy Organization Journal|January 4, 2013
What is an Allergist?: Reconciled Document Incorporating Member Society Comments, September 3, 2007Sergio Del Giacco, Lanny J Rosenwasser, Carlos D Crisci, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 8, 2008
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonistAilsa J Frew, Ralph K Lindemann, Ben P Martin, et al.
JCI Insight|November 22, 2022
ATR represents a therapeutic vulnerability in clear cell renal cell carcinomaPhilipp Seidel, Anne Rubarth, Kyra Zodel, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 2, 2007
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphomaR K Lindemann, A Newbold, K F Whitecross, et al.
Molecular and Cellular Biology|December 3, 2003
Generation and analysis of Siah2 mutant miceIan J Frew, Vicki E Hammond, Ross A Dickins, et al.
Pageof 32